{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:38:06Z","timestamp":1784734686301,"version":"3.55.0"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"NIDA","doi-asserted-by":"publisher","award":["R01DA023281"],"award-info":[{"award-number":["R01DA023281"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"NIDA","doi-asserted-by":"publisher","award":["R41DA044894"],"award-info":[{"award-number":["R41DA044894"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.pnpbp.2022.110599","type":"journal-article","created":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T01:07:48Z","timestamp":1656983268000},"page":"110599","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["PPL-103: A mixed opioid partial agonist with desirable anti-cocaine properties"],"prefix":"10.1016","volume":"119","author":[{"given":"Andrea","family":"Cippitelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Zribi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Toll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5387","key":"10.1016\/j.pnpbp.2022.110599_bb0005","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1126\/science.282.5387.298","article-title":"Transition from moderate to excessive drug intake: change in hedonic set point","volume":"282","author":"Ahmed","year":"1998","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.pnpbp.2022.110599_bb0010","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/adb.12629","article-title":"Revisiting long-access versus short-access cocaine self-administration in rats: intermittent intake promotes addiction symptoms independent of session length","volume":"24","author":"Allain","year":"2019","journal-title":"Addict. Biol."},{"key":"10.1016\/j.pnpbp.2022.110599_bb0015","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.neubiorev.2015.06.012","article-title":"How fast and how often: the pharmacokinetics of drug use are decisive in addiction","volume":"56","author":"Allain","year":"2015","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"1","key":"10.1016\/j.pnpbp.2022.110599_bb0020","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1017\/S1092852913000722","article-title":"Compulsivity, impulsivity, and the DSM-5 process","volume":"19","author":"Berlin","year":"2014","journal-title":"CNS Spectr."},{"key":"10.1016\/j.pnpbp.2022.110599_bb0025","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/B978-0-12-420118-7.00010-X","article-title":"Mixed kappa\/mu partial opioid agonists as potential treatments for cocaine dependence","volume":"69","author":"Bidlack","year":"2014","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.pnpbp.2022.110599_bb0030","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.brainres.2009.08.062","article-title":"The dynorphin\/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors","volume":"1314","author":"Bruchas","year":"2010","journal-title":"Brain Res."},{"issue":"11","key":"10.1016\/j.pnpbp.2022.110599_bb0035","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1097\/j.pain.0000000000001318","article-title":"Influence of neuropathic pain on nicotinic acetylcholine receptor plasticity and behavioral responses to nicotine in rats","volume":"159","author":"Brunori","year":"2018","journal-title":"Pain"},{"issue":"9","key":"10.1016\/j.pnpbp.2022.110599_bb0040","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1038\/npp.2015.27","article-title":"A double-blind, placebo-controlled trial to evaluate the safety, tolerability, and pharmacokinetics of single, escalating oral Doses of JDTic","volume":"40","author":"Buda","year":"2015","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"10.1016\/j.pnpbp.2022.110599_bb0045","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.tins.2012.05.005","article-title":"Kappa-opioid receptor\/dynorphin system: genetic and pharmacotherapeutic implications for addiction","volume":"35","author":"Butelman","year":"2012","journal-title":"Trends Neurosci."},{"issue":"33","key":"10.1016\/j.pnpbp.2022.110599_bb0050","doi-asserted-by":"crossref","first-page":"5597","DOI":"10.2174\/092986712803988947","article-title":"Neuropathological alterations in cocaine abuse","volume":"19","author":"Buttner","year":"2012","journal-title":"Curr. Med. Chem."},{"issue":"12","key":"10.1016\/j.pnpbp.2022.110599_bb0055","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1038\/npp.2013.136","article-title":"Temporal pattern of cocaine intake determines tolerance vs sensitization of cocaine effects at the dopamine transporter","volume":"38","author":"Calipari","year":"2013","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.pnpbp.2022.110599_bb0060","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/jnc.12452","article-title":"Extended access of cocaine self-administration results in tolerance to the dopamine-elevating and locomotor-stimulating effects of cocaine","volume":"128","author":"Calipari","year":"2014","journal-title":"J. Neurochem."},{"issue":"6","key":"10.1016\/j.pnpbp.2022.110599_bb0065","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1021\/jm301783x","article-title":"Development of kappa opioid receptor antagonists","volume":"56","author":"Carroll","year":"2013","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.pnpbp.2022.110599_bb0070","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/BF02244812","article-title":"Effects of buprenorphine on self-administration of cocaine and a nondrug reinforcer in rats","volume":"106","author":"Carroll","year":"1992","journal-title":"Psychopharmacology"},{"issue":"9","key":"10.1016\/j.pnpbp.2022.110599_bb0075","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1038\/npp.2015.74","article-title":"Kappa antagonist JDTic in phase 1 clinical trial","volume":"40","author":"Chavkin","year":"2015","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1016\/j.pnpbp.2022.110599_bb0080","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s00213-018-4883-y","article-title":"Differential regulation of alcohol taking and seeking by antagonism at alpha4beta2 and alpha3beta4 nAChRs","volume":"235","author":"Cippitelli","year":"2018","journal-title":"Psychopharmacology"},{"issue":"6","key":"10.1016\/j.pnpbp.2022.110599_bb0085","doi-asserted-by":"crossref","DOI":"10.1111\/adb.12844","article-title":"Potent and selective NOP receptor activation reduces cocaine self-administration in rats by lowering hedonic set point","volume":"25","author":"Cippitelli","year":"2020","journal-title":"Addict. Biol."},{"key":"10.1016\/j.pnpbp.2022.110599_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109045","article-title":"PPL-138 (BU10038): a bifunctional NOP\/mu partial agonist that reduces cocaine self-administration in rats","volume":"211","author":"Cippitelli","year":"2022","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.pnpbp.2022.110599_bb0095","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1124\/pr.115.011668","article-title":"Evaluation of the \u201cpipeline\u201d for development of medications for cocaine use disorder: a review of translational preclinical, human laboratory, and clinical trial research","volume":"68","author":"Czoty","year":"2016","journal-title":"Pharmacol. Rev."},{"issue":"5","key":"10.1016\/j.pnpbp.2022.110599_bb0100","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/00001756-199305000-00020","article-title":"Cocaine self-administration increases preprodynorphin, but not c-fos, mRNA in rat striatum","volume":"4","author":"Daunais","year":"1993","journal-title":"Neuroreport"},{"issue":"3","key":"10.1016\/j.pnpbp.2022.110599_bb0105","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1124\/jpet.117.241042","article-title":"Cebranopadol blocks the escalation of cocaine intake and conditioned reinstatement of cocaine seeking in rats","volume":"362","author":"de Guglielmo","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"9810","key":"10.1016\/j.pnpbp.2022.110599_bb0110","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0140-6736(11)61138-0","article-title":"Extent of illicit drug use and dependence, and their contribution to the global burden of disease","volume":"379","author":"Degenhardt","year":"2012","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.pnpbp.2022.110599_bb0115","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1097\/ALN.0000000000003848","article-title":"Functional profile of systemic and intrathecal cebranopadol in nonhuman primates","volume":"135","author":"Ding","year":"2021","journal-title":"Anesthesiology"},{"issue":"Pt A","key":"10.1016\/j.pnpbp.2022.110599_bb0120","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.pnpbp.2018.01.002","article-title":"Modeling cocaine relapse in rodents: behavioral considerations and circuit mechanisms","volume":"87","author":"Farrell","year":"2018","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.pnpbp.2022.110599_bb0125","first-page":"198","article-title":"Evaluation of a sustained-release formulation of buprenorphine for analgesia in rats","volume":"50","author":"Foley","year":"2011","journal-title":"J. Am. Assoc. Lab. Anim. Sci."},{"issue":"3","key":"10.1016\/j.pnpbp.2022.110599_bb0130","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/clpt.1991.32","article-title":"Human pharmacology and abuse potential of nalmefene","volume":"49","author":"Fudala","year":"1991","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.pnpbp.2022.110599_bb0135","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00213-008-1079-x","article-title":"Controversies in translational research: drug self-administration","volume":"199","author":"Haney","year":"2008","journal-title":"Psychopharmacology"},{"issue":"11","key":"10.1016\/j.pnpbp.2022.110599_bb0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0239780","article-title":"Cocaine vaccine dAd5GNE protects against moderate daily and high-dose \u201cbinge\u201d cocaine use","volume":"15","author":"Havlicek","year":"2020","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.pnpbp.2022.110599_bb0145","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1038\/s41386-017-0006-4","article-title":"A single, extinction-based treatment with a kappa opioid receptor agonist elicits a long-term reduction in cocaine relapse","volume":"43","author":"Heinsbroek","year":"2018","journal-title":"Neuropsychopharmacology"},{"issue":"11","key":"10.1016\/j.pnpbp.2022.110599_bb0150","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.biopsych.2018.07.022","article-title":"Increased number and activity of a lateral subpopulation of hypothalamic orexin\/hypocretin neurons underlies the expression of an addicted state in rats","volume":"85","author":"James","year":"2019","journal-title":"Biol. Psychiatry"},{"issue":"1\u20132","key":"10.1016\/j.pnpbp.2022.110599_bb0155","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s00213-003-1393-2","article-title":"Brain circuitry and the reinstatement of cocaine-seeking behavior","volume":"168","author":"Kalivas","year":"2003","journal-title":"Psychopharmacology"},{"issue":"4","key":"10.1016\/j.pnpbp.2022.110599_bb0160","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s00213-019-5164-0","article-title":"The transition to cocaine addiction: the importance of pharmacokinetics for preclinical models","volume":"236","author":"Kawa","year":"2019","journal-title":"Psychopharmacology"},{"issue":"4","key":"10.1016\/j.pnpbp.2022.110599_bb0165","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1111\/ejn.14418","article-title":"Incentive and dopamine sensitization produced by intermittent but not long access cocaine self-administration","volume":"50","author":"Kawa","year":"2019","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.pnpbp.2022.110599_bb0170","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3389\/fpsyt.2017.00052","article-title":"In vitro and in vivo profile of PPL-101 and PPL-103: mixed opioid partial agonist analgesics with low abuse potential","volume":"8","author":"Khroyan","year":"2017","journal-title":"Front. Psychiatry"},{"issue":"6","key":"10.1016\/j.pnpbp.2022.110599_bb0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1000412","article-title":"Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research","volume":"8","author":"Kilkenny","year":"2010","journal-title":"PLoS Biol."},{"issue":"8","key":"10.1016\/j.pnpbp.2022.110599_bb0180","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1517\/13543784.2014.915312","article-title":"Drugs currently in phase II clinical trials for cocaine addiction","volume":"23","author":"Kim","year":"2014","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"5","key":"10.1016\/j.pnpbp.2022.110599_bb0185","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.biopsych.2011.03.017","article-title":"Kappa opioid receptor signaling in the basolateral amygdala regulates conditioned fear and anxiety in rats","volume":"70","author":"Knoll","year":"2011","journal-title":"Biol. Psychiatry"},{"issue":"8","key":"10.1016\/j.pnpbp.2022.110599_bb0190","doi-asserted-by":"crossref","first-page":"899","DOI":"10.2174\/187152711799219334","article-title":"Anti-cocaine vaccine based on coupling a cocaine analog to a disrupted adenovirus","volume":"10","author":"Koob","year":"2011","journal-title":"CNS Neurol. Disord. Drug Targets"},{"issue":"Pt B","key":"10.1016\/j.pnpbp.2022.110599_bb0195","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.neuropharm.2013.05.024","article-title":"Addiction as a stress surfeit disorder","volume":"76","author":"Koob","year":"2014","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.pnpbp.2022.110599_bb0200","first-page":"15","article-title":"Buprenorphine for cocaine and opiate dependence","volume":"28","author":"Kosten","year":"1992","journal-title":"Psychopharmacol. Bull."},{"issue":"1","key":"10.1016\/j.pnpbp.2022.110599_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/pr.57.1.1","article-title":"Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments","volume":"57","author":"Kreek","year":"2005","journal-title":"Pharmacol. Rev."},{"issue":"2","key":"10.1016\/j.pnpbp.2022.110599_bb0210","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1523\/JNEUROSCI.4458-07.2008","article-title":"The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system","volume":"28","author":"Land","year":"2008","journal-title":"J. Neurosci."},{"issue":"45","key":"10.1016\/j.pnpbp.2022.110599_bb0215","doi-asserted-by":"crossref","first-page":"19168","DOI":"10.1073\/pnas.0910705106","article-title":"Activation of the kappa opioid receptor in the dorsal raphe nucleus mediates the aversive effects of stress and reinstates drug seeking","volume":"106","author":"Land","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"18","key":"10.1016\/j.pnpbp.2022.110599_bb0220","doi-asserted-by":"crossref","first-page":"7856","DOI":"10.1523\/JNEUROSCI.22-18-07856.2002","article-title":"Additive effect of stress and drug cues on reinstatement of ethanol seeking: exacerbation by history of dependence and role of concurrent activation of corticotropin-releasing factor and opioid mechanisms","volume":"22","author":"Liu","year":"2002","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.pnpbp.2022.110599_bb0225","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0376-8716(95)01195-1","article-title":"Buprenorphine-induced alterations of cocaine\u2019s reinforcing effects in rhesus monkey: a dose-response analysis","volume":"40","author":"Lukas","year":"1995","journal-title":"Drug Alcohol Depend."},{"issue":"1","key":"10.1016\/j.pnpbp.2022.110599_bb0230","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s00213-004-1778-x","article-title":"Effects of extended access to high versus low cocaine doses on self-administration, cocaine-induced reinstatement and brain mRNA levels in rats","volume":"175","author":"Mantsch","year":"2004","journal-title":"Psychopharmacology"},{"issue":"6","key":"10.1016\/j.pnpbp.2022.110599_bb0235","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/0893-133X(95)00274-H","article-title":"Preclinical evaluation of pharmacotherapies for treatment of cocaine and opioid abuse using drug self-administration procedures","volume":"14","author":"Mello","year":"1996","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.pnpbp.2022.110599_bb0240","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pbb.2009.09.002","article-title":"Effect of kappa-opioid receptor agonists U69593, U50488H, spiradoline and salvinorin a on cocaine-induced drug-seeking in rats","volume":"94","author":"Morani","year":"2009","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"8","key":"10.1016\/j.pnpbp.2022.110599_bb0245","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1176\/appi.ajp.162.8.1423","article-title":"Anticraving medications for relapse prevention: a possible new class of psychoactive medications","volume":"162","author":"O\u2019Brien","year":"2005","journal-title":"Am. J. Psychiatry"},{"issue":"17","key":"10.1016\/j.pnpbp.2022.110599_bb0250","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1097\/00001756-200312020-00019","article-title":"Increased motivation for self-administered cocaine after escalated cocaine intake","volume":"14","author":"Paterson","year":"2003","journal-title":"Neuroreport"},{"issue":"2","key":"10.1016\/j.pnpbp.2022.110599_bb0255","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.neuroscience.2010.04.060","article-title":"Acute withdrawal from chronic escalating-dose binge cocaine administration alters kappa opioid receptor stimulation of [35S] guanosine 5\u2019-O-[gamma-thio]triphosphate acid binding in the rat ventral tegmental area","volume":"169","author":"Piras","year":"2010","journal-title":"Neuroscience"},{"issue":"2","key":"10.1016\/j.pnpbp.2022.110599_bb0260","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1369-1600.2007.00061.x","article-title":"New developments in the pharmacotherapy of cocaine abuse","volume":"12","author":"Preti","year":"2007","journal-title":"Addict. Biol."},{"issue":"1","key":"10.1016\/j.pnpbp.2022.110599_bb9074","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0165-0270(95)00153-0","article-title":"Progressive ratio schedules in drug self-administration studies in rats: a method to evaluate reinforcing efficacy","volume":"66","author":"Richardson","year":"1996","journal-title":"J Neurosci Methods"},{"issue":"8","key":"10.1016\/j.pnpbp.2022.110599_bb0265","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17081216","article-title":"Distinct effects of nalmefene on dopamine uptake rates and kappa opioid receptor activity in the nucleus accumbens following chronic intermittent ethanol exposure","volume":"17","author":"Rose","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.pnpbp.2022.110599_bb0270","series-title":"Key Substance Use and Mental Health Indicators in the United States: Results from the 2017 National Survey on Drug Use and Health","author":"SAMHSA","year":"2018"},{"issue":"4","key":"10.1016\/j.pnpbp.2022.110599_bb0275","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s002130051016","article-title":"U69593, a kappa-opioid agonist, decreases cocaine self-administration and decreases cocaine-produced drug-seeking","volume":"144","author":"Schenk","year":"1999","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2022.110599_bb0280","article-title":"Hypocretin neurotransmission within the central amygdala mediates escalated cocaine Self-administration and stress-induced reinstatement in rats","author":"Schmeichel","year":"2016","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2022.110599_bb0285","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jsat.2010.03.014","article-title":"Self-treatment: illicit buprenorphine use by opioid-dependent treatment seekers","volume":"39","author":"Schuman-Olivier","year":"2010","journal-title":"J. Subst. Abus. Treat."},{"issue":"1\u20132","key":"10.1016\/j.pnpbp.2022.110599_bb0290","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00213-002-1224-x","article-title":"The reinstatement model of drug relapse: history, methodology and major findings","volume":"168","author":"Shaham","year":"2003","journal-title":"Psychopharmacology"},{"issue":"5","key":"10.1016\/j.pnpbp.2022.110599_bb0295","doi-asserted-by":"crossref","first-page":"442","DOI":"10.2174\/187152708786927813","article-title":"Targeting endogenous mu- and delta-opioid receptor systems for the treatment of drug addiction","volume":"7","author":"Shippenberg","year":"2008","journal-title":"CNS Neurol. Disord. Drug Targets"},{"issue":"5","key":"10.1016\/j.pnpbp.2022.110599_bb0300","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1111\/j.1471-4159.2004.02589.x","article-title":"Stress increases dynorphin immunoreactivity in limbic brain regions and dynorphin antagonism produces antidepressant-like effects","volume":"90","author":"Shirayama","year":"2004","journal-title":"J. Neurochem."},{"issue":"8","key":"10.1016\/j.pnpbp.2022.110599_bb0305","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1038\/npp.2009.28","article-title":"Role of mu- and delta-opioid receptors in the nucleus accumbens in cocaine-seeking behavior","volume":"34","author":"Simmons","year":"2009","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.pnpbp.2022.110599_bb0310","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/S0022-3565(25)22808-7","article-title":"Cocaine selectively increases striatonigral dynorphin levels by a dopaminergic mechanism","volume":"250","author":"Sivam","year":"1989","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"4","key":"10.1016\/j.pnpbp.2022.110599_bb0315","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0169-328X(93)90133-A","article-title":"\u2018Binge\u2019 cocaine administration induces a sustained increase of prodynorphin mRNA in rat caudate-putamen","volume":"19","author":"Spangler","year":"1993","journal-title":"Brain Res. Mol. Brain Res."},{"issue":"1","key":"10.1016\/j.pnpbp.2022.110599_bb0320","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0169-328X(95)00319-N","article-title":"Regulation of kappa opioid receptor mRNA in the rat brain by \u201cbinge\u201d pattern cocaine administration and correlation with preprodynorphin mRNA","volume":"38","author":"Spangler","year":"1996","journal-title":"Brain Res. Mol. Brain Res."},{"key":"10.1016\/j.pnpbp.2022.110599_bb0325","series-title":"World Drug Report","author":"UNODC","year":"2014"},{"issue":"13","key":"10.1016\/j.pnpbp.2022.110599_bb0330","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1097\/00001756-199408150-00018","article-title":"Repeated cocaine administration upregulates kappa and mu, but not delta, opioid receptors","volume":"5","author":"Unterwald","year":"1994","journal-title":"Neuroreport"},{"issue":"2","key":"10.1016\/j.pnpbp.2022.110599_bb0335","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1124\/jpet.107.125484","article-title":"Kappa agonist-induced reinstatement of cocaine seeking in squirrel monkeys: a role for opioid and stress-related mechanisms","volume":"323","author":"Valdez","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"4","key":"10.1016\/j.pnpbp.2022.110599_bb0340","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00213-019-05444-4","article-title":"Effects of Kappa opioid receptor blockade by LY2444296 HCl, a selective short-acting antagonist, during chronic extended access cocaine self-administration and re-exposure in rat","volume":"237","author":"Valenza","year":"2020","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1016\/j.pnpbp.2022.110599_bb0345","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00213-013-3195-5","article-title":"Role of kappa-opioid receptors in stress and anxiety-related behavior","volume":"229","author":"Van\u2019t Veer","year":"2013","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2022.110599_bb0350","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/bs.pbr.2015.08.004","article-title":"Animal models of drug relapse and craving: from drug priming-induced reinstatement to incubation of craving after voluntary abstinence","volume":"224","author":"Venniro","year":"2016","journal-title":"Prog. Brain Res."},{"issue":"2","key":"10.1016\/j.pnpbp.2022.110599_bb0355","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/npp.2014.188","article-title":"Compulsive-like responding for opioid analgesics in rats with extended access","volume":"40","author":"Wade","year":"2015","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.pnpbp.2022.110599_bb0360","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1124\/jpet.106.113340","article-title":"Effects of dose and session duration on cocaine self-administration in rats","volume":"320","author":"Wee","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"4","key":"10.1016\/j.pnpbp.2022.110599_bb0365","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s00213-009-1563-y","article-title":"Inhibition of kappa opioid receptors attenuated increased cocaine intake in rats with extended access to cocaine","volume":"205","author":"Wee","year":"2009","journal-title":"Psychopharmacology"},{"issue":"13","key":"10.1016\/j.pnpbp.2022.110599_bb0370","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1038\/npp.2011.165","article-title":"Brain-cocaine concentrations determine the dose self-administered by rats on a novel behaviorally dependent dosing schedule","volume":"36","author":"Zimmer","year":"2011","journal-title":"Neuropsychopharmacology"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584622000914?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584622000914?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T20:01:11Z","timestamp":1759521671000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584622000914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":75,"alternative-id":["S0278584622000914"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2022.110599","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PPL-103: A mixed opioid partial agonist with desirable anti-cocaine properties","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2022.110599","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110599"}}